On June 3, Praxis Precision Medicines rose 5.7% in pre-market trading, trading at $273.0/share, with trading volume of $63,700. The stock rebounded following a steep 15.36% intraday decline in the prior session triggered by the failure of its Power1 study to meet the primary efficacy endpoint in refractory focal onset seizures.

While the Power1 trial for core pipeline candidate Vormatrigine did not achieve its primary endpoint, the study reached the key secondary endpoint of 50% responder rate, with the 30mg dose group demonstrating more pronounced seizure frequency reduction. Additionally, Vormatrigine exhibited favorable tolerability, with discontinuation rates due to adverse events controlled below 10%. These positive signals preserved a potential clinical development pathway for the drug.

After the market absorbed the initial shock of the primary endpoint miss, investors appeared to reassess the data package more constructively. The combination of meaningful secondary endpoint results and a clean safety profile suggested that the program may not be entirely derailed, prompting the pre-market recovery from the prior session low of $283.47.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)